What substances does the Instanosis 3-in-1 Test Strip detect?

The Instanosis 3-in-1 Multiplex Test Strip simultaneously detects Fentanyl, Xylazine, and Medetomidine in a single lateral flow assay, optimized specifically for forensic and field harm reduction applications.

What are the analytical cut-off sensitivities for this 3-in-1 multiplex strip?

This high-sensitivity strip is calibrated to precise, reliable thresholds: 2 ng/mL cut-off for Fentanyl, 10 ng/mL for Xylazine, and 50 ng/mL for Medetomidine.

Can this multiplex test strip be used for clinical hospital diagnostics?

No. This specific 3-in-1 multiplex test strip is strictly intended for Forensic and Field Harm Reduction applications only, and is not cleared for IVD or clinical laboratory diagnostic workflows.

3-in-1 Fentanyl/Xylazine/Medetomidine test strip, for forensic and harm reduction applications

Product Overview

The Instanosis 3-in-1 Fentanyl, Xylazine, and Medetomidine Test Strip is an ultra-sensitive, NIH-funded lateral flow assay designed for forensic and harm reduction applications. Manufactured in the USA, this advanced screening tool simultaneously identifies three major illicit substances on a single strip, utilizing highly specific analytical cut-offs: 2 ng/mL for fentanyl, 10 ng/mL for xylazine, and 50 ng/mL for medetomidine. Requiring only 1/10th of the sample volume demanded by standard market alternatives, it delivers rapid, accurate field results to detect emerging synthetic adulterants and protect public health networks.

Technical Specifications & Key Data

This multi-drug immunoassay is explicitly engineered to address highly complex polysubstance configurations within the illicit supply chain:

Multiplexed Detection Profile: Screens for Fentanyl, Xylazine, and Medetomidine simultaneously.
Analytical Limits of Detection (LOD):
- Fentanyl: 2 ng/mL
- Xylazine: 10 ng/mL
- Medetomidine: 50 ng/mL
Enantiomeric Optimization: Unlike legacy field tests that experience high false-negative rates by only selecting for single isomers, the Instanosis strip is optimized for complete cross-reactivity with both dexmedetomidine and levomedetomidine racemic structures.
Sample Preservation: Operates at a micro-volume threshold, reducing required test sample amount by 90% compared to commercial competitors.
Quality & Funding Benchmarks: Developed under strict FDA QMSR quality control standards via National Institutes of Health (NIH) grant funding and proudly Made in the U.S.

Public Health & Epidemiological Context

The introduction of medetomidine (an alpha-2 adrenergic receptor agonist approved strictly for veterinary sedation) represents a critical shift in the synthetic opioid crisis (Zhu et al, Lancet Reg Health Am, 2025).

High Potency Threat: Medetomidine exhibits an overall clinical potency 200- to 300-fold greater than xylazine, substantially escalating the risk of profound sedation, bradycardia, and severe respiratory depression.
Co-Adulteration Prevalence: Federal public health tracking indicates that approximately 98% of illegal drug samples testing positive for medetomidine are co-adulterated with fentanyl (CDC Health Alert Network).
Geographic Vulnerability: Sentinel site surveillance and wastewater testing programs have confirmed rapid geographic expansion, tracking heavy clusters across the Northeast, Midwest, and Southern United States (CDC Health Alert Network).

Frequently Asked Questions (FAQ)

Q1: What substances does this specific Instanosis 3-in-1 test strip screen for?

A: This specific immunoassay simultaneously screens for Fentanyl, Xylazine (a common sedative adulterant), and Medetomidine (a highly potent emerging synthetic sedative often referred to on the street as “rhino tranq”), all using a single sample application.

Q2: What are the exact analytical cut-off levels for the strip?

A: The precise technical cut-off levels are engineered at 2 ng/mL for fentanyl, 10 ng/mL for xylazine, and 50 ng/mL for medetomidine. This provides far greater sensitivity than historical standard test strips that often default to a 1,000 ng/mL threshold.

Q3: Why is tracking medetomidine considered a public health priority?

A: Medetomidine is roughly 200 to 300 times more potent than xylazine (Zhu et al, Lancet Reg Health Am, 2025). Because it causes severe, prolonged central nervous system depression and bradycardia that cannot be directly reversed by naloxone alone, field checking tools are vital for harm reduction teams to alert local populations.

Q4: How does this product handle the chiral properties of medetomidine?

A: Illicit medetomidine typically appears in the field as a racemic mixture of different enantiomers. While some brands fail to detect certain variations, the Instanosis strip features a formulation that recognizes both chemical isomers to prevent false negatives.

Q5: How much sample is needed for the test?

A: The lateral flow design utilizes high-affinity antibody pairings that require just 1/10th of the sample (0.5 mg) compared to competing brands, preserving critical forensic evidence or primary chemical mixtures during testing.

Q6: Is this product intended for clinical patient diagnostics?

A: No. This product is strictly labeled and intended for forensic investigations, harm reduction surveillance, and laboratory research applications only.